Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events

作者: Benedito A Carneiro , Jason B Kaplan , Francis J Giles

DOI: 10.1586/17474086.2015.1041910

关键词:

摘要: Current treatment recommendations for chronic myeloid leukemia (CML) are guided by results from multiple clinical trials involving tyrosine kinase inhibitors that target BCR-ABL1. Consideration of the unique benefits and potential risks associated with each inhibitor approved CML is crucial physicians when recommending most appropriate therapy patient. Monitoring prompt management adverse events may increase adherence to optimize patient outcomes. Here we provide an overview efficacy safety CML, as well key reported these agents in patients CML.

参考文章(105)
Noriyoshi Iriyama, Shin Fujisawa, Maki Hagihara, Chikashi Yoshida, Hisashi Wakita, Shigeru Chiba, Shinichiro Okamoto, Kawakami Kimihiro, Naoki Takezako, Takashi Kumagai, Koiti Inokuchi, Kazuma Ohyashiki, Jun Taguchi, Shingo Yano, Tadahiko Igarashi, Yasuji Kouzai, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study Blood. ,vol. 124, pp. 3142- 3142 ,(2014) , 10.1182/BLOOD.V124.21.3142.3142
Jorge E. Cortes, Andreas Hochhaus, Dong-Wook Kim, Neil P. Shah, Jiri Mayer, Philip Rowlings, Hirohisa Nakamae, M. Brigid Bradley-Garelik, Hesham Mohamed, Hagop M. Kantarjian, Giuseppe Saglio, Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response Blood. ,vol. 122, pp. 653- 653 ,(2013) , 10.1182/BLOOD.V122.21.653.653
Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian, Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial Blood. ,vol. 124, pp. 3135- 3135 ,(2014) , 10.1182/BLOOD.V124.21.3135.3135
Carlo Gambacorti‐Passerini, Jorge E. Cortes, Jeff H. Lipton, Anna Dmoszynska, Raymond S. Wong, Victor Rossiev, Dmitri Pavlov, Karin Gogat Marchant, Ladan Duvillié, Navin Khattry, Hagop M. Kantarjian, Tim H. Brümmendorf, Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. American Journal of Hematology. ,vol. 89, pp. 947- 953 ,(2014) , 10.1002/AJH.23788
Torsten Dahlén, Gustaf Edgren, Martin Höglund, Mats Lambe, Magnus Björkholm, Fredrik Sandin, Anders Själander, Johan Richter, Lotta Ohm, Magnus Bäck, Leif Stenke, Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia : Data from Swedish Population-Based Registries Blood. ,vol. 124, pp. 3134- 3134 ,(2014) , 10.1182/BLOOD.V124.21.3134.3134
Josu de la Fuente, André Baruchel, Andrea Biondi, Eveline de Bont, Marie-Françoise Dresse, Meinolf Suttorp, Frédéric Millot, , Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years British Journal of Haematology. ,vol. 167, pp. 33- 47 ,(2014) , 10.1111/BJH.12977
Hesam Hekmatjou, Gail J. Roboz, Ellen K. Ritchie, Sangmin Lee, Pinkal Desai, Joseph M. Scandura, Sandra Allen-Bard, Paul Christos, Richard T. Silver, Eric J. Feldman, Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib Blood. ,vol. 124, pp. 1811- 1811 ,(2014) , 10.1182/BLOOD.V124.21.1811.1811
Young-Woo Jeon, Sung-Eun Lee, Soo-Hyun Kim, Soo-Young Choi, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center Blood. ,vol. 122, pp. 4017- 4017 ,(2013) , 10.1182/BLOOD.V122.21.4017.4017
Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Yaping Shou, Neil J. Gallagher, Rick Blakesley, Michele Baccarani, Jorge Cortes, Philipp D. le Coutre, Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood. ,vol. 117, pp. 1141- 1145 ,(2011) , 10.1182/BLOOD-2010-03-277152